# Compounded Tirzepatide Side Effects: The Drug, and the Vial

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-14 | Updated: 2026-11-02

Canonical page: https://glpwatchdog.org/research/compounded-tirzepatide-side-effects

> Most compounded tirzepatide side effects are tirzepatide side effects, documented in the approved product's label and trials. A smaller set comes from the preparation: a pharmacy-set concentration, added ingredients, and an adverse-event pathway that may never count your report.

## Key points

- In the pooled Zepbound weight-reduction trials, 56% of tirzepatide patients had a gastrointestinal adverse reaction against 30% on placebo; severe ones ran 1.7–3.1% against 1%.
- Nausea was reported by 25–29% of tirzepatide patients by dose versus 8% on placebo, and clustered during dose escalation rather than spreading evenly.
- There is no trial of any compounded tirzepatide formulation. The entire evidence base belongs to Mounjaro and Zepbound.
- A compounded vial's concentration is chosen by the pharmacy, and FDA ties adverse events, some requiring hospitalization, to patients measuring their own doses.
- A 503A pharmacy is not required to report your adverse event to FDA; a registered 503B outsourcing facility is, which is why FDA says compounded reports are underreported.

Most of what people call a compounded tirzepatide side effect is a tirzepatide side effect. Nausea, diarrhea, vomiting and constipation dominate the approved product's trial record, they cluster during dose escalation, and they do not change because a pharmacy mixed the vial.[1][3] What the compounded version adds is a second, smaller category with a different cause: errors and unknowns that come from the preparation rather than the drug. Keeping the two apart is the only way to know whether what you are feeling is expected.

> **Symptoms go to your prescriber, not to a website.** Severe or persistent abdominal pain, vomiting that stops you keeping fluids down, signs of an allergic reaction, or a lump or swelling in your neck are reasons to seek care rather than to read further. Nothing on this page is a reason to change a dose, skip one or stop on your own.

## Where the side effect list actually comes from

There is no trial of compounded tirzepatide. The evidence everyone quotes, including the sellers, belongs to Mounjaro and Zepbound ([how a compounded vial differs from Zepbound](https://glpwatchdog.org/research/compounded-tirzepatide-vs-zepbound)), and it was collected in the phase 3 programs that supported their approvals. In the obesity trial that carried the weight-management approval, 2,539 adults were randomized to tirzepatide or placebo for 72 weeks, with a 20-week dose-escalation period built in. The authors' summary of the safety findings was that gastrointestinal effects were the most frequent, were mostly mild to moderate, and came mainly during that escalation.[3]

That timing is the most useful part of the trial record, because it tells you when to expect trouble: in the weeks after each step up, not evenly across the year.

*Adverse reactions in the pooled Zepbound weight-reduction trials. The label's threshold for this table is 2% of treated patients, plus a rate above placebo. Percentages as printed.[1]*

| Adverse reaction | Placebo | 5 mg | 10 mg | 15 mg |
| --- | --- | --- | --- | --- |
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Vomiting | 2% | 8% | 11% | 13% |
| Constipation | 5% | 17% | 14% | 11% |
| Abdominal pain | 5% | 9% | 9% | 10% |
| Injection site reactions | 2% | 6% | 8% | 8% |
| Hair loss | 1% | 5% | 4% | 5% |

Taken together rather than symptom by symptom, gastrointestinal adverse reactions were reported by 56 percent of patients at each of the three doses, against 30 percent on placebo.[1] Severe ones were much rarer: 1.7, 2.5 and 3.1 percent by dose, against 1 percent on placebo.[1] Between 4.8 and 6.7 percent of patients stopped the drug for an adverse reaction, compared with 3.4 percent on placebo, and most who stopped did so in the first few months.[1]

The numbers are lower in the diabetes population, where the same molecule is sold as Mounjaro: nausea ran 12, 15 and 18 percent by dose against 4 percent on placebo in the pooled placebo-controlled trials.[2] And in [the head-to-head against semaglutide in type 2 diabetes](https://glpwatchdog.org/research/a-composite-is-only-its-components), nausea on tirzepatide was 17 to 22 percent against 18 percent on semaglutide 1 mg. The figures are close enough that the class, not the particular molecule, is doing most of the work.[4]

## The serious warnings the approved label carries

These belong to the drug, which means they apply to a compounded vial containing it. The label opens with a boxed warning: in rats, tirzepatide caused dose-dependent and duration-dependent thyroid C-cell tumors, and whether that happens in humans is not determined. Two groups must not take it at all. One is anyone whose family or medical history includes medullary thyroid carcinoma. The other is anyone carrying multiple endocrine neoplasia syndrome type 2, which the label names as a contraindication in its own right.[1]

- **Severe gastrointestinal reactions**, sometimes severe enough to stop treatment. Not recommended in severe gastroparesis.[1]
- **Acute kidney injury from volume depletion**, mostly reported in people who became dehydrated through vomiting or diarrhea.[1]
- **Acute gallbladder disease** and **acute pancreatitis**.[1]
- **Hypersensitivity reactions**, including anaphylaxis and angioedema.[1]
- **Hypoglycemia**, particularly alongside insulin or a sulfonylurea.[1]
- **Diabetic retinopathy complications** in people with type 2 diabetes.[1]
- **Pulmonary aspiration under general anesthesia, or under deep sedation**. Tell any surgeon or anesthetist that you are taking it.[1]

The list does not rank tirzepatide against other drugs. In the type 2 diabetes head-to-head, the serious adverse event rate ran 5 to 7 percent on tirzepatide against 3 percent on semaglutide,[4] a real difference inside one trial, but not a general ranking of the two drugs.

## Now the part that is specific to a compounded vial

Everything above would be equally true of a prescription filled at a retail pharmacy. The four risks below are not. They come with the compounded vial.

### 1. You are measuring the dose, and the concentration is not standardized

An approved tirzepatide presentation states its strength on a label FDA reviewed. Zepbound's multi-dose vials, for instance, run from 4.17 mg/mL to 25 mg/mL, each delivering four fixed 0.6 mL doses, and every one of those figures is printed in the prescribing information.[1] A compounded vial's concentration is whatever the compounding pharmacy chose. No approved label states it, nothing standardizes it between pharmacies, and it can change when you switch supplier without the milligram number on your prescription changing at all.

FDA has reported multiple adverse events, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide, and it describes the mechanism as patients measuring and self-administering incorrect doses, with clinicians miscalculating in some cases.[5] It separately reports adverse events that may relate to compounded semaglutide or tirzepatide prescribed at doses beyond the approved label (more per dose, more often, or escalated faster). Some were serious, and what drove people to seek medical attention was the gastrointestinal cluster: sickness, vomiting, loose stools, stomach pain and constipation.[5]

> **Notice what that means for interpreting your own symptoms.** An overdose of tirzepatide and an ordinary dose of tirzepatide produce symptoms from the same list. Feeling sick after a dose does not tell you which one you had. The only way to rule out the arithmetic is to check it: ask your pharmacy for the concentration in milligrams per milliliter, and confirm the volume of one dose in the units printed on your syringe. Do that with the prescriber, not by adjusting anything yourself. If you think you injected too much, see [what happens after a GLP-1 overdose](https://glpwatchdog.org/research/glp1-overdose-what-happens).

### 2. There may be ingredients the trials never studied

The approved product's ingredient list is short. Besides tirzepatide, Zepbound's single-dose presentations contain water, sodium chloride and a phosphate buffer salt; the multi-dose vial and KwikPen add three more inactive ingredients: benzyl alcohol, glycerin and phenol. No vitamin appears anywhere on it.[1]

Compounded vials frequently carry more. In the one published survey of this market, pharmacy researchers searched compounder websites in early 2025 and cataloged 33 distinct products, one-third of them tirzepatide. Of all 33, 48 percent combined the GLP-1 with cyanocobalamin, [glycine, niacinamide](https://glpwatchdog.org/research/glp1-with-glycine-b6-or-niacinamide), docusate or ondansetron. The authors' conclusion was that they found little justification for adding nutrients or docusate sodium to an injectable product.[6] MEDLINE indexes that paper as an editorial, so treat it as a structured look at what is for sale with the authors' judgment attached, not as a measurement.

So if your vial contains something the approved product does not, no line in the trial record describes what that ingredient does in an injectable tirzepatide preparation, in either direction. It has not been tested for benefit and it has not been tested for harm. We work through the same problem on the other molecule in [why compounded semaglutide is mixed with B12](https://glpwatchdog.org/research/semaglutide-compounded-with-b12).

### 3. Your reaction may never reach anyone who counts it

This one is invisible to the person it happens to. An outsourcing facility registered under 503B is required to report adverse events to FDA.[7] A state-licensed 503A pharmacy that is not an outsourcing facility is not, and FDA says so explicitly, adding that adverse events from compounded versions of these drugs are therefore likely underreported.[5] As of May 31, 2026 the agency had received 990 reports involving compounded semaglutide and more than 730 involving compounded tirzepatide, and it notes that many of them look consistent with what is already known about the approved products.[5]

So the safety signal for a compounded product accumulates more slowly than for an approved one, from a system that does not require the reports. You can file your own report directly through FDA's MedWatch program, and it is worth doing. Which kind of compounder made your vial decides whether your reaction is counted anywhere, and our [pharmacy register](https://glpwatchdog.org/pharmacies) exists to answer that question.

### 4. A batch problem is a possibility that an approved product mostly forecloses

Injectable GLP-1 drugs require refrigeration, and FDA has received complaints of compounded ones arriving warm or with inadequate ice, which can affect quality; its advice is not to use them.[5] It has also documented fraudulent compounded semaglutide and tirzepatide whose labels name pharmacies that do not exist, or real pharmacies that did not make the product. One reported adverse event, with injection site redness, swelling, pain and a lump, was tied to a product labeled as compounded tirzepatide from a pharmacy that had not compounded it.[5] An injection site reaction is on the approved label too,[1] so establish where the vial came from before you try to interpret one.

## The two columns, side by side

*Which effects belong to the drug and which to the preparation*

| What you might experience | Where it comes from |
| --- | --- |
| Nausea, vomiting, diarrhea, constipation, abdominal pain, especially after a dose increase | **Drug class.** Documented across the approved product's trials and label, clustered during dose escalation.[1][3] |
| Injection site reactions, fatigue, hair loss, eructation, reflux | **Drug class.** All appear in the approved label's adverse reaction table above 2%.[1] |
| Pancreatitis, gallbladder disease, kidney injury after dehydration, hypersensitivity, retinopathy complications | **Drug class.** Labeled warnings for the approved product, and they carry over to any product containing the molecule.[1] |
| Symptoms out of proportion to the dose you believe you took | **Compounding-specific.** Concentration is set by the pharmacy and the dose is drawn by you; FDA has tied adverse events, some requiring hospitalization, to exactly this measurement step.[5] |
| Anything attributable to a second ingredient in the vial | **Compounding-specific and uncharacterized.** Combination formulations are common in this market and no trial record describes their effects.[6] |
| A reaction that appears after switching pharmacies at the same milligram dose | **Compounding-specific.** Nothing standardizes concentration between compounders, so the volume you draw may be right for the old vial and wrong for the new one.[1][5] |

## What to do with a symptom

1. **Get care first for the serious ones.** Stomach pain that will not settle, vomiting that stops you keeping fluids down, a swollen face or throat, difficulty breathing, or a lump in your neck are not things to research. They are things to call about.
2. **Check the arithmetic before you change anything.** Ask the pharmacy for the concentration in milligrams per milliliter, and for the dose volume in the units on your syringe. Bring both numbers to your prescriber. This is the one check that is unique to a compounded vial and it takes one phone call.
3. **Ask what else is in it.** If there is a second active ingredient, say so when you describe the symptom, because the person advising you cannot assume the vial contains tirzepatide alone.
4. **Report it to FDA yourself** through MedWatch. If a 503A pharmacy made your vial, no one else is required to.[5]
5. **Do not solve it by adjusting the dose.** Escalation timing is where most of these reactions live, and changing it is a clinical decision.

Step two goes faster when you already know who made the vial. [Claya](https://glpwatchdog.org/reviews/claya) names both of its compounding pharmacies, with addresses, [Elara Health and Wellness](https://glpwatchdog.org/reviews/elara-health-and-wellness) names four 503A pharmacies, and [Found Youth](https://glpwatchdog.org/reviews/found-youth) gives its pharmacy’s address and phone number. [AHBARx](https://glpwatchdog.org/reviews/ahbarx) is the opposite case: its terms leave the pharmacy name as an unfilled placeholder, so the question has to go to the seller first.

The route changes the picture as well, since the approved label describes an injection. [VigorMeds](https://glpwatchdog.org/reviews/vigormeds) sells compounded tirzepatide as under-the-tongue drops, [Nova](https://glpwatchdog.org/reviews/nova-trynova) as a daily sublingual tablet, [Emerge Weight Loss](https://glpwatchdog.org/reviews/emerge-weight-loss) as an oral dissolving tablet next to its injections, and Found Youth as drops or a microdose shot as well as a standard one; side effects from those forms are not in the trial record. [California Trim Clinic](https://glpwatchdog.org/reviews/california-trim-clinic) requires a free discovery call before any order, which is a natural moment to ask the three questions above, and the same questions apply at [Mochi Health](https://glpwatchdog.org/reviews/mochi-health), an obesity medicine telehealth seller that also lists compounded tirzepatide.

If the answer to any of the first three questions is a slogan rather than a number, that is information about your seller. Our [safety breakdown for compounded tirzepatide](https://glpwatchdog.org/research/is-compounded-tirzepatide-safe) covers the regulatory side of the same problem, the [ranked board](https://glpwatchdog.org/best/compounded-tirzepatide) records what each program discloses about its pharmacy, and the [price tracker](https://glpwatchdog.org/price-tracker) carries a dated figure for every program we follow.

## Frequently asked questions

### Does compounded tirzepatide have different side effects from Mounjaro or Zepbound?

The molecule's effects are the same, and they are the ones in the approved label: mostly gastrointestinal, mostly during dose escalation. What differs is a second set of risks that come from the preparation rather than the drug: a concentration set by the pharmacy rather than an approved label, ingredients that may not be in the approved product, and no requirement on a state-licensed pharmacy to report your reaction to FDA. No study compares harm rates between compounded and approved tirzepatide, so anyone quoting you such a comparison is inventing it.

### How long do the side effects last?

In the trials of the approved product, nausea, vomiting and diarrhea mostly appeared during dose escalation and decreased over time, and most people who stopped the drug for an adverse reaction did so in the first few months. That is a pattern across thousands of people, not a prediction about you, and how your own escalation is handled is a conversation with your prescriber.

### Could my side effects mean the dose is wrong rather than too strong for me?

It is possible and it is worth ruling out. FDA has received adverse event reports, some involving hospitalization, that may relate to dosing errors with compounded injectable semaglutide, arising from patients measuring incorrect doses and in some cases clinicians miscalculating them. Because a compounded vial's concentration is chosen by the pharmacy, the same milligram prescription can mean a different volume at a different pharmacy. Ask for the concentration and the dose volume and take both to your prescriber.

### Is the B12 or other added ingredient causing this?

Nobody can tell you. Combination formulations are common. In a 2025 survey of compounder websites, 48 percent of the products cataloged paired the GLP-1 with cyanocobalamin, glycine, niacinamide, docusate or ondansetron, but no trial record describes what those additions do in an injectable GLP-1 preparation. That is an absence of evidence in both directions, and it is a reason to tell your prescriber exactly what is in your vial.

### Who do I report a reaction to?

Your prescriber and the pharmacy named on the label first. Then FDA's MedWatch program directly. Outsourcing facilities registered under section 503B are required to report adverse events to FDA; state-licensed pharmacies that are not outsourcing facilities are not, which is why FDA says adverse events from compounded GLP-1 products are likely underreported.

### Does hair loss come from the drug or from losing weight quickly?

Hair loss is in the approved label's adverse reaction table, reported by 4 to 5 percent of tirzepatide-treated patients against 1 percent on placebo in the pooled weight-reduction trials. The label records that it occurred; it does not settle the mechanism, and rapid weight loss from any cause is associated with hair shedding. Either way it belongs in the conversation with your prescriber rather than in a decision to stop.

## References

1. Eli Lilly and Company ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information (boxed warning; sections 3, 5, 6.1, 11). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
2. Eli Lilly and Company MOUNJARO (tirzepatide) injection, for subcutaneous use — prescribing information (sections 5, 6.1). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387(3):205-216. 2022. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
4. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385(6):503-515. 2021. PMID: 34170647. https://pubmed.ncbi.nlm.nih.gov/34170647/
5. U.S. Food and Drug Administration FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA Drug Alerts and Statements. 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
6. Belcourt J, Sapowadia A, White CM. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. Ann Pharmacother 2026;60(9):902-906 (editorial). 2026. PMID: 41689811. https://pubmed.ncbi.nlm.nih.gov/41689811/
7. U.S. Food and Drug Administration Information for Outsourcing Facilities. FDA Human Drug Compounding. 2026. https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities

---

Cite as: GLP Watchdog, Ruth Calder, "Compounded Tirzepatide Side Effects: The Drug, and the Vial", published 2026-08-14, updated 2026-11-02. https://glpwatchdog.org/research/compounded-tirzepatide-side-effects

Canonical HTML page: https://glpwatchdog.org/research/compounded-tirzepatide-side-effects

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.